{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:36:28Z","timestamp":1784763388790,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Health and Social Protection, Morocco"},{"name":"Africa Centres for Disease Control and Prevention (Africa CDC) through its Saving Lives and Livelihoods (SLL) program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Assessing the prevalence of SARS-CoV-2 IgG positivity through population-based serological surveys is crucial for monitoring COVID-19 vaccination efforts. In this study, we evaluated SARS-CoV-2 IgG positivity within a provincial cohort to understand the magnitude of the humoral response against the SARS-CoV-2 vaccine and to inform evidence-based public health decisions. A community-based cross-sectional seroprevalence study was conducted, involving 10,669 participants who received various vaccines (two doses for BBIBP-CorV\/Sinopharm, Covishield vaccine, and Pfizer\/BioNTech, and one dose for Johnson &amp; Johnson's Janssen COVID-19 vaccine). The study spanned 16 provinces in the Casablanca-Settat region from February to June 2022, during which comprehensive demographic and comorbidity data were collected. We screened samples for the presence of IgG antibodies using the SARS-CoV-2 IgG II Quant assay, which quantifies antibodies against the receptor-binding domain (RBD) of the spike (S) protein, measured on the Abbott Architect i2000SR. The overall crude seroprevalence was 96% (95% CI: 95.6\u201396.3%), and after adjustment for assay performance, it was estimated as 96.2% (95% CI: 95.7\u201396.6). The adjusted overall seroprevalences according to vaccine brands showed no significant difference (96% for BBIBP-CorV\/Sinopharm, 97% for ChAdOx1 nCoV-19\/Oxford\/AstraZeneca, 98.5% for BNT162b2\/Pfizer-BioNTech, and 98% for Janssen) (<jats:italic>p<\/jats:italic>\u2009=\u20090.099). Participants of older age, female sex, those with a history of previous COVID-19 infection, and those with certain chronic diseases were more likely to be seropositive among ChAdOx1 nCoV-19\/Oxford\/AstraZeneca and BBIBP-CorV\/Sinopharm vaccinee groups. Median RBD antibody concentrations were 2355 AU\/mL, 3714 AU\/mL, 5838 AU\/mL, and 2495 AU\/mL, respectively, after two doses of BBIBP-CorV\/Sinopharm, ChAdOx1 nCoV-19\/Oxford\/AstraZeneca, BNT162b2\/Pfizer-BioNTech, and after one dose of Janssen (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Furthermore, we observed that participants vaccinated with ChAdOx1 nCoV-19\/Oxford\/AstraZeneca and BBIBP-CorV\/Sinopharm with comorbid chronic diseases exhibited a more pronounced response to vaccination compared to those without comorbidities. In contrast, no significant differences were observed among Pfizer-vaccinated participants (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). In conclusion, our serosurvey findings indicate that all four investigated vaccines provide a robust humoral immune response in the majority of participants (more than 96% of participants had antibodies against SARS-CoV-2). The BNT162b2 vaccine was found to be effective in eliciting a strong humoral response compared to the other three vaccines. However, challenges still remain in examining the dynamics and durability of immunoprotection in the Moroccan context.<\/jats:p>","DOI":"10.1038\/s41598-024-58498-6","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T06:01:50Z","timestamp":1712124110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco"],"prefix":"10.1038","volume":"14","author":[{"given":"Sayeh","family":"Ezzikouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raji","family":"Tajudeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Majidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soad","family":"Redwane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa","family":"Aqillouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merawi","family":"Aragaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosoka","family":"Papa Fallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senga","family":"Sembuche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Batcho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kabwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Gonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumaima","family":"Laazaazia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohcine","family":"Elmessaoudi-Idrissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Meziane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Ainahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u2019hammed","family":"Sarih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E.","family":"Ogwell Ouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahmane","family":"Maaroufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"58498_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus outbreak of global health concern. Lancet 395, 470\u2013473. https:\/\/doi.org\/10.1016\/S0140-6736(20)30185-9 (2020).","journal-title":"Lancet"},{"key":"58498_CR2","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0140-6736(21)02835-X","volume":"399","author":"PB McIntyre","year":"2022","unstructured":"McIntyre, P. B. et al. COVID-19 vaccine strategies must focus on severe disease and global equity. Lancet 399, 406\u2013410. https:\/\/doi.org\/10.1016\/S0140-6736(21)02835-X (2022).","journal-title":"Lancet"},{"key":"58498_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577 (2020).","journal-title":"N. Engl. J. Med."},{"key":"58498_CR4","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1186\/s12889-022-14016-9","volume":"22","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health 22, 1584. https:\/\/doi.org\/10.1186\/s12889-022-14016-9 (2022).","journal-title":"BMC Public Health"},{"key":"58498_CR5","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey, A. R. et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N. Engl. J. Med. 385, 2348\u20132360. https:\/\/doi.org\/10.1056\/NEJMoa2105290 (2021).","journal-title":"N. Engl. J. Med."},{"key":"58498_CR6","doi-asserted-by":"publisher","unstructured":"Sadoff, J. et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201. https:\/\/doi.org\/10.1056\/NEJMoa2101544 (2021).","DOI":"10.1056\/NEJMoa2101544"},{"key":"58498_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111. https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1 (2021).","journal-title":"Lancet"},{"key":"58498_CR8","doi-asserted-by":"publisher","DOI":"10.20344\/amp.18528","author":"I Kislaya","year":"2022","unstructured":"Kislaya, I. et al. SARS-CoV-2 seroprevalence following a large-scale vaccination campaign in Portugal: Results of the national serological survey, September\u2013November 2021. Acta Med. Port https:\/\/doi.org\/10.20344\/amp.18528 (2022).","journal-title":"Acta Med. Port"},{"key":"58498_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01181-21","volume":"10","author":"H Fujigaki","year":"2022","unstructured":"Fujigaki, H. et al. Antibody responses to BNT162b2 vaccination in Japan: Monitoring vaccine efficacy by measuring IgG antibodies against the receptor-binding domain of SARS-CoV-2. Microbiol. Spectr. 10, e0118121. https:\/\/doi.org\/10.1128\/spectrum.01181-21 (2022).","journal-title":"Microbiol. Spectr."},{"key":"58498_CR10","doi-asserted-by":"publisher","unstructured":"Castro Dopico, X., Ols, S., Lor\u00e9, K. & Karlsson Hedestam, G. B. Immunity to SARS-CoV-2 induced by infection or vaccination. J. Intern. Med. 291, 32\u201350. https:\/\/doi.org\/10.1111\/joim.13372 (2022).","DOI":"10.1111\/joim.13372"},{"key":"58498_CR11","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2372-2383.e2379. https:\/\/doi.org\/10.1016\/j.cell.2021.03.013 (2021).","journal-title":"Cell"},{"key":"58498_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00288-21","volume":"59","author":"E English","year":"2021","unstructured":"English, E. et al. Performance of the Abbott SARS-CoV-2 IgG II quantitative antibody assay including the new variants of concern, VOC 202012\/V1 (United Kingdom) and VOC 202012\/V2 (South Africa), and first steps towards global harmonization of COVID-19 antibody methods. J. Clin. Microbiol. 59, e0028821 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"58498_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/ije\/dyab010","volume":"50","author":"E Bendavid","year":"2021","unstructured":"Bendavid, E. et al. COVID-19 antibody seroprevalence in Santa Clara County, California. Int. J. Epidemiol. 50, 410\u2013419. https:\/\/doi.org\/10.1093\/ije\/dyab010 (2021).","journal-title":"Int. J. Epidemiol."},{"key":"58498_CR14","doi-asserted-by":"publisher","unstructured":"Ranjbar Kermani, F. et al. Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic. Transfus. Clin. Biol. S1246\u20137820, 00246\u201300244. https:\/\/doi.org\/10.1016\/j.tracli.2022.09.003 (2022).","DOI":"10.1016\/j.tracli.2022.09.003"},{"key":"58498_CR15","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3390\/vaccines10030465","volume":"10","author":"N Assaid","year":"2022","unstructured":"Assaid, N. et al. Anti-SARS-CoV-2 antibody responses 5 months post complete vaccination of moroccan healthcare workers. Vaccines 10, 465. https:\/\/doi.org\/10.3390\/vaccines10030465 (2022).","journal-title":"Vaccines"},{"key":"58498_CR16","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3390\/vaccines10091462","volume":"10","author":"AS Abdelhafiz","year":"2022","unstructured":"Abdelhafiz, A. S. et al. Sinopharm\u2019s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 vaccine are associated with a comparable immune response against SARS-CoV-2. Vaccines 10, 1462. https:\/\/doi.org\/10.3390\/vaccines10091462 (2022).","journal-title":"Vaccines"},{"key":"58498_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00341-21","volume":"9","author":"SE Wheeler","year":"2021","unstructured":"Wheeler, S. E. et al. Differential antibody response to mRNA COVID-19 vaccines in healthy subjects. Microbiol. Spectr. 9, e0034121. https:\/\/doi.org\/10.1128\/Spectrum.00341-21 (2021).","journal-title":"Microbiol. Spectr."},{"key":"58498_CR18","doi-asserted-by":"publisher","first-page":"e02596","DOI":"10.1128\/JCM.02596-20","volume":"59","author":"LH Harritsh\u00f8j","year":"2021","unstructured":"Harritsh\u00f8j, L. H. et al. Comparison of 16 serological SARS-CoV-2 immunoassays in 16 clinical laboratories. J. Clin. Microbiol. 59, e02596-e12520. https:\/\/doi.org\/10.1128\/JCM.02596-20 (2021).","journal-title":"J. Clin. Microbiol."},{"key":"58498_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02811-22","volume":"10","author":"YJ Lin","year":"2022","unstructured":"Lin, Y. J. et al. Utilization of the Abbott SARS-CoV-2 IgG II quant assay to identify high-titer anti-SARS-CoV-2 neutralizing plasma against wild-type and variant SARS-CoV-2 viruses. Microbiol. Spectr. 10, e0281122. https:\/\/doi.org\/10.1128\/spectrum.02811-22 (2022).","journal-title":"Microbiol. Spectr."},{"key":"58498_CR20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. N. Engl. J. Med. 385, e84. https:\/\/doi.org\/10.1056\/NEJMoa2114583 (2021).","journal-title":"N. Engl. J. Med."},{"key":"58498_CR21","unstructured":"MAP. COVID-19: Health Ministry Declares End of Omicron Second Wave in Morocco. (https:\/\/www.maroc.ma\/en\/news\/covid-19-health-ministry-declares-end-omicron-second-wave-morocco, accessed on 11 November, 2022) ."},{"key":"58498_CR22","doi-asserted-by":"publisher","first-page":"2200619","DOI":"10.2807\/1560-7917.ES.2022.27.33.2200619","volume":"27","author":"J Castilla","year":"2022","unstructured":"Castilla, J. et al. Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022. Euro Surveill. 27, 2200619. https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.33.2200619 (2022).","journal-title":"Euro Surveill."},{"key":"58498_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101655","author":"HJ Zar","year":"2022","unstructured":"Zar, H. J. et al. Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa. EClinical Med. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101655 (2022).","journal-title":"EClinical Med."},{"key":"58498_CR24","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1016\/j.vaccine.2022.03.069","volume":"40","author":"MA Sughayer","year":"2022","unstructured":"Sughayer, M. A. et al. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies. Vaccine 40, 2841\u20132847. https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.069 (2022).","journal-title":"Vaccine"},{"key":"58498_CR25","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.26355\/eurrev_202207_29321","volume":"26","author":"E Fodor","year":"2022","unstructured":"Fodor, E. et al. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization. Eur. Rev. Med. Pharmacol. Sci. 26, 5297\u20135306. https:\/\/doi.org\/10.26355\/eurrev_202207_29321 (2022).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"58498_CR26","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.chom.2021.11.004","volume":"29","author":"NJ Dashdorj","year":"2021","unstructured":"Dashdorj, N. J. et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell Host Microbe 29, 1738-1743.e1734. https:\/\/doi.org\/10.1016\/j.chom.2021.11.004 (2021).","journal-title":"Cell Host Microbe"},{"key":"58498_CR27","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e","volume":"70","author":"WH Self","year":"2021","unstructured":"Self, W. H. et al. Comparative effectiveness of moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions\u2014United States, March-August 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 1337\u20131343. https:\/\/doi.org\/10.15585\/mmwr.mm7038e (2021).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"58498_CR28","doi-asserted-by":"publisher","first-page":"11180","DOI":"10.1021\/acsnano.1c03972","volume":"15","author":"FJ Ibarrondo","year":"2021","unstructured":"Ibarrondo, F. J. et al. Primary, recall, and decay kinetics of SARS-CoV-2 vaccine antibody responses. ACS Nano 15, 11180\u201311191. https:\/\/doi.org\/10.1021\/acsnano.1c03972 (2021).","journal-title":"ACS Nano"},{"key":"58498_CR29","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.3390\/cells10081952","volume":"10","author":"A Tretyn","year":"2021","unstructured":"Tretyn, A. et al. Differences in the concentration of anti-SARS-CoV-2 IgG antibodies post-COVID-19 Recovery or post-vaccination. Cells 10, 1952. https:\/\/doi.org\/10.3390\/cells10081952 (2021).","journal-title":"Cells"},{"key":"58498_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N AlKaabi","year":"2021","unstructured":"AlKaabi, N. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: A randomized clinical trial. JAMA 326, 35\u201345. https:\/\/doi.org\/10.1001\/jama.2021.8565 (2021).","journal-title":"JAMA"},{"key":"58498_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00430-022-00744-7","volume":"211","author":"AY Popova","year":"2022","unstructured":"Popova, A. Y. et al. SARS-CoV-2 herd immunity of the Kyrgyz population in 2021. Med. Microbiol. Immunol. 211, 195\u2013210. https:\/\/doi.org\/10.1007\/s00430-022-00744-7 (2022).","journal-title":"Med. Microbiol. Immunol."},{"key":"58498_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molimm.2022.01.009","volume":"143","author":"MN Badano","year":"2022","unstructured":"Badano, M. N. et al. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2. Mol. Immunol. 143, 94\u201399. https:\/\/doi.org\/10.1016\/j.molimm.2022.01.009 (2022).","journal-title":"Mol. Immunol."},{"key":"58498_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263468","volume":"17","author":"V Petrovi\u0107","year":"2022","unstructured":"Petrovi\u0107, V., Vukovi\u0107, V., Pati\u0107, A., Markovi\u0107, M. & Risti\u0107, M. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection\u2013A comparative study from Novi Sad, Serbia. PLoS ONE 17, e0263468. https:\/\/doi.org\/10.1371\/journal.pone.0263468 (2022).","journal-title":"PLoS ONE"},{"key":"58498_CR34","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/vaccines10071020","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Evaluation of immunogenicity and safety of vero cell-derived inactivated COVID-19 vaccine in older patients with hypertension and diabetes mellitus. Vaccines 10, 1020. https:\/\/doi.org\/10.3390\/vaccines10071020 (2022).","journal-title":"Vaccines"},{"issue":"343\u2013346","key":"58498_CR35","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.15585\/mmwr.mm6912e2","volume":"69","author":"Team., C. C.-R. Severe Outcomes Among Patients with Coronavirus Disease","year":"2019","unstructured":"Team., C. C.-R. Severe Outcomes Among Patients with Coronavirus Disease. (COVID-19)\u2014United States, February 12-March 16, 2020. MMWR Morb. Mortal. Wkly. Rep. 69(343\u2013346), 2020. https:\/\/doi.org\/10.15585\/mmwr.mm6912e2 (2019).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"58498_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632814","volume":"12","author":"H Luo","year":"2021","unstructured":"Luo, H. et al. The characterization of disease severity associated IgG subclasses response in COVID-19 patients. Front. Immunol. 12, 632814. https:\/\/doi.org\/10.3389\/fimmu.2021.632814 (2021).","journal-title":"Front. Immunol."},{"key":"58498_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ijregi.2022.04.006","volume":"3","author":"TR Bhuiyan","year":"2022","unstructured":"Bhuiyan, T. R. et al. Covishield vaccine induces robust immune responses in Bangladeshi adults. IJID Reg. 3, 211\u2013217. https:\/\/doi.org\/10.1016\/j.ijregi.2022.04.006 (2022).","journal-title":"IJID Reg."},{"key":"58498_CR38","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396, 1979\u20131993. https:\/\/doi.org\/10.1016\/S0140-6736(20)32466-1 (2021).","journal-title":"Lancet"},{"key":"58498_CR39","unstructured":"Senarathne, U. et al. in EuroMedLab (ed Walter de Gruyter) S94\u2013S835 (Clin Chem Lab Med)."},{"key":"58498_CR40","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.2147\/IDR.S335414","volume":"14","author":"A Hoque","year":"2021","unstructured":"Hoque, A. et al. Antibody response to ChAdOx1-nCoV-19 vaccine among recipients in Bangladesh: A prospective observational study. Infect. Drug Resist. 14, 5491\u20135500. https:\/\/doi.org\/10.2147\/IDR.S335414 (2021).","journal-title":"Infect. Drug Resist."},{"key":"58498_CR41","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450. https:\/\/doi.org\/10.1056\/NEJMoa2027906 (2020).","journal-title":"N. Engl. J. Med."},{"key":"58498_CR42","doi-asserted-by":"publisher","first-page":"18929","DOI":"10.1038\/s41598-022-21797-x","volume":"12","author":"Y Kobashi","year":"2022","unstructured":"Kobashi, Y. et al. Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey. Sci. Rep. 12, 18929. https:\/\/doi.org\/10.1038\/s41598-022-21797-x (2022).","journal-title":"Sci. Rep."},{"key":"58498_CR43","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/vaccines10071002","volume":"10","author":"X Aguilera","year":"2022","unstructured":"Aguilera, X. et al. Immunization and SARS-CoV-2 antibody seroprevalence in a country with high vaccination coverage: Lessons from Chile. Vaccines 10, 1002. https:\/\/doi.org\/10.3390\/vaccines10071002 (2022).","journal-title":"Vaccines"},{"key":"58498_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277827","volume":"17","author":"I Sarrigeorgiou","year":"2022","unstructured":"Sarrigeorgiou, I. et al. Combined monitoring of IgG and IgA anti-Spike and anti-Receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers. PLoS ONE 17, e0277827. https:\/\/doi.org\/10.1371\/journal.pone.0277827 (2022).","journal-title":"PLoS ONE"},{"key":"58498_CR45","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","volume":"6","author":"J Wei","year":"2021","unstructured":"Wei, J. et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat. Microbiol. 6, 1140\u20131149. https:\/\/doi.org\/10.1038\/s41564-021-00947-3 (2021).","journal-title":"Nat. Microbiol."},{"key":"58498_CR46","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.1016\/S2666-5247(21)00305-0","volume":"3","author":"B Barin","year":"2022","unstructured":"Barin, B., Kasap, U., Sel\u00e7uk, F., Volkan, E. & Ulu\u00e7kan, \u00d6. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe 3, e274\u2013e283. https:\/\/doi.org\/10.1016\/S2666-5247(21)00305-0 (2022).","journal-title":"Lancet Microbe"},{"key":"58498_CR47","doi-asserted-by":"publisher","DOI":"10.1080\/13814788.2022.2149732","author":"E Meyers","year":"2022","unstructured":"Meyers, E. et al. Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign. Eur. J. Gen. Pract. https:\/\/doi.org\/10.1080\/13814788.2022.2149732 (2022).","journal-title":"Eur. J. Gen. Pract."},{"key":"58498_CR48","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101492R","volume":"36","author":"G Shapira","year":"2022","unstructured":"Shapira, G. et al. Population differences in antibody response to SARS-CoV-2 infection and BNT162b2 vaccination. FASEB J. 36, e22223. https:\/\/doi.org\/10.1096\/fj.202101492R (2022).","journal-title":"FASEB J."},{"key":"58498_CR49","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fimmu.2020.01662","volume":"11","author":"A Guihot","year":"2020","unstructured":"Guihot, A., Litvinova, E., Autran, B., Debr\u00e9, P. & Vieillard, V. Cell-Mediated immune responses to COVID-19 infection. Front. Immunol. 11, 1662. https:\/\/doi.org\/10.3389\/fimmu.2020.01662 (2020).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58498-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T06:05:19Z","timestamp":1712124319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["58498"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-58498-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"assertion":[{"value":"24 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7817"}}